Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SION

Sionna Therapeutics Inc

Feb 21 • 04:00PM ET

19.76

Dollar change -0.34
Percentage change -1.72	%

Healthcare • Biotechnology • USA • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	48.81%	Shs Outstand	42.52M	Perf Week	-2.56%
Market Cap	840.20M	Forward P/E	-	EPS next Y	-	Insider Trans	20.08%	Shs Float	21.77M	Perf Month	-
Income	-	PEG	-	EPS next Q	-	Inst Own	31.51%	Short Float	-	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	27.41%	Short Ratio	-	Perf Half Y	-
Book/sh	-2.70	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf Year	-
Cash/sh	0.91	P/C	21.81	EPS next 5Y	-	ROE	-	52W Range	19.26 - 25.19	Perf YTD	-20.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-21.56%	Beta	-
Dividend TTM	-	Quick Ratio	4.88	Sales past 5Y	0.00%	Gross Margin	-	52W Low	2.60%	ATR (14)	2.12
Dividend Ex-Date	-	Current Ratio	4.88	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	-	Volatility	6.69% -
Employees	28	Debt/Eq	0.31	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.29	EPS Q/Q	-	Payout	-	Rel Volume	0.48	Prev Close	20.10
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	386.96K	Price	19.76
SMA20	-4.87%	SMA50	-4.87%	SMA200	-4.87%	Trades		Volume	185,548	Change	-1.72%

Feb-17-25 04:43PM	Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year? (Insider Monkey)
Feb-10-25 04:03PM	Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -11.04% -8.23%
Feb-06-25 07:51PM	Sionna Therapeutics Prices Upsized Initial Public Offering (GlobeNewswire)
03:13PM	Vertex challenger Sionna prices $191M IPO (BioPharma Dive)

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a robust pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TPG GP A, LLC	10% Owner	Feb 10 '25	Buy	18.00	1,125,000	20,250,000	6,684,962	Feb 12 05:21 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 10 '25	Buy	18.00	1,125,000	20,250,000	6,923,365	Feb 10 05:04 PM
ORBIMED ADVISORS LLC	Director	Feb 10 '25	Buy	18.00	550,000	9,900,000	3,704,959	Feb 10 04:28 PM
Thompson Peter A.	Director	Feb 10 '25	Buy	18.00	550,000	9,900,000	3,704,959	Feb 10 04:05 PM
Booth Bruce	Director	Feb 10 '25	Buy	18.00	60,000	1,080,000	807,727	Feb 10 04:05 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 10 '25	Buy	18.00	60,000	1,080,000	807,727	Feb 10 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SION

Sionna Therapeutics Inc

Upgrade your FINVIZ experience